Literature DB >> 21187469

Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol.

Beverly D Lyn-Cook1, Sulma I Mohammed, Cornelius Davis, Beverly Word, Aaron Haefele, Honggang Wang, George Hammons.   

Abstract

Pancreatic cancer has a poor prognosis, mainly due to lack of effective therapies. This study demonstrated the ability of dietary agent, indole-3-carbinol (I3C), to lower the LD(50) of gemcitabine (Gemzar) in decreasing growth of both male (MiaPaca2) and female (SU86.86) pancreatic cancer cells. Female pancreatic cancer cells were more resistant to gemcitabine alone. Additionally, RT-PCR analysis of MiaPaca2 cells treated with 1, 10 or 100 μM of I3C showed that I3C reactivated the tumor suppressor gene p16INK4a in pancreatic cancer cells. Methylated-specific PCR analysis indicated that I3C demethylated the promoter region of p16 INK4a, which was methylated in the untreated cancer cells. p16INK4a inactivation through promoter hypermethylation is considered an early event in pancreatic carcinogenesis. A positive control using 5-azacytidine also reactivated p16INK4a. This study demonstrated the potential of I3C, a possible non-toxic hypomethylating agent, combined with the anticancer agent, gemcitabine, to be a powerful strategy for treating pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187469

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.

Authors:  Majid Safa; Behnaz Tavasoli; Rima Manafi; Fatemeh Kiani; Meysam Kashiri; Saber Ebrahimi; Ahmad Kazemi
Journal:  Tumour Biol       Date:  2015-01-15

2.  Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.

Authors:  Justine M Grixti; Steve O'Hagan; Philip J Day; Douglas B Kell
Journal:  Front Pharmacol       Date:  2017-03-27       Impact factor: 5.810

3.  A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.

Authors:  Vsevolod I Kiselev; Levon A Ashrafyan; Ekaterina L Muyzhnek; Evgeniya V Gerfanova; Irina B Antonova; Olga I Aleshikova; Fazlul H Sarkar
Journal:  BMC Cancer       Date:  2018-09-20       Impact factor: 4.430

4.  Mechanisms and therapeutic implications of cell death induction by indole compounds.

Authors:  Aamir Ahmad; Wael A Sakr; Km Wahidur Rahman
Journal:  Cancers (Basel)       Date:  2011-07-19       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.